Category: St. Jude Medical
Medtronic suspends its worldwide renal denervation trials after the U.S. pivotal trial of its Symplicity device fails to meet its efficacy endpoint.
Medtronic (NYSE:MDT) said its Symplicty renal denervation device failed to meet the efficacy endpoint in a U.S. pivotal trial, Symplicity HTN-3, prompting it to suspend enrollment in its other Symplicity trials around the world and to say that a writedown of its renal denervation assets is likely.
Medtech titans and Minnesota rivals Medtronic and St. Jude Medical lands patents for a sheath steering system and an implantable medical device antenna.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Medtech titan St. Jude Medical gets an end-of-the-year boost, setting record highs day after day for nearly a week until peaking at $63.15 the day after Christmas.
Medical device giant St. Jude Medical (NYSE:STJ) ended 2013 with a boost, notching a new Wall Street high-water mark of $63.15 on December 26.
Medtronic plans to boost its footprint in Puerto Rico with a $6 million expansion that will bring 150 new jobs to the Isla del Encanto.
St. Jude Medical lands CE Mark approval in the European Union for a larger, 25mm version of its Portico replacement heart valve.
St. Jude Medical (NYSE:STJ) said it won CE Mark approval in the European Union for the 25mm version of its Portico replacement heart valve.
The U.S. Circuit Court of Appeals refuses to reopen the a patent infringement lawsuit brought by St. Jude Medical against AccessClosure and its artery closure technology.
Medtech titan St. Jude Medical's (NYSE:STJ) lost a bid to appeal its lawsuit against AccessClosure after a federal court refused to hear a patent infringement claim over artery closure devices.